Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2.

Gould JC, Kasichayanula S, Shepperly DC, Boulton DW.

Regul Toxicol Pharmacol. 2013 Oct;67(1):89-97. doi: 10.1016/j.yrtph.2013.07.002. Epub 2013 Jul 11.

PMID:
23851069
2.

Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.

Yang L, Li H, Li H, Bui A, Chang M, Liu X, Kasichayanula S, Griffen SC, Lacreta FP, Boulton DW.

Clin Ther. 2013 Aug;35(8):1211-1222.e2. doi: 10.1016/j.clinthera.2013.06.017. Epub 2013 Aug 2.

PMID:
23910664
3.

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.

Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M.

Clin Pharmacol Ther. 2009 May;85(5):520-6. doi: 10.1038/clpt.2008.251. Epub 2009 Jan 7.

PMID:
19129748
4.

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW.

Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. Review.

PMID:
24105299
5.

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, Humphreys WG, Boulton DW.

Br J Clin Pharmacol. 2013 Sep;76(3):432-44. doi: 10.1111/bcp.12056.

6.

Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor.

Tirmenstein M, Dorr TE, Janovitz EB, Hagan D, Abell LM, Onorato JM, Whaley JM, Graziano MJ, Reilly TP.

Int J Toxicol. 2013 Sep-Oct;32(5):336-50. doi: 10.1177/1091581813505331. Epub 2013 Oct 4.

PMID:
24097127
7.

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.

Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M.

Clin Pharmacol Ther. 2009 May;85(5):513-9. doi: 10.1038/clpt.2008.250. Epub 2009 Jan 7. Erratum in: Clin Pharmacol Ther. 2009 May;85(5):558.

PMID:
19129749
8.

Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.

Kasichayanula S, Liu X, Griffen SC, Lacreta FP, Boulton DW.

Diabetes Obes Metab. 2013 Mar;15(3):280-3. doi: 10.1111/dom.12024. Epub 2012 Nov 19.

PMID:
23061428
9.

Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects.

Kasichayanula S, Liu X, Zhang W, Pfister M, Reele SB, Aubry AF, LaCreta FP, Boulton DW.

Diabetes Obes Metab. 2011 Aug;13(8):770-3. doi: 10.1111/j.1463-1326.2011.01397.x.

PMID:
21435141
10.

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.

Nagata T, Fukazawa M, Honda K, Yata T, Kawai M, Yamane M, Murao N, Yamaguchi K, Kato M, Mitsui T, Suzuki Y, Ikeda S, Kawabe Y.

Am J Physiol Endocrinol Metab. 2013 Feb 15;304(4):E414-23. doi: 10.1152/ajpendo.00545.2012. Epub 2012 Dec 18.

11.

Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.

Veltkamp SA, Kadokura T, Krauwinkel WJ, Smulders RA.

Clin Drug Investig. 2011 Dec 1;31(12):839-51. doi: 10.2165/11594330-000000000-00000.

PMID:
21877761
12.

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.

Neumiller JJ, White JR Jr, Campbell RK.

Drugs. 2010 Mar 5;70(4):377-85. doi: 10.2165/11318680-000000000-00000. Review.

PMID:
20205482
14.

Dapagliflozin: an emerging treatment option in type 2 diabetes.

Kipnes M.

Expert Opin Investig Drugs. 2009 Mar;18(3):327-34. doi: 10.1517/13543780902766794 . Review.

PMID:
19243283
15.

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.

Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M.

J Pharmacol Exp Ther. 2007 Jan;320(1):323-30. Epub 2006 Oct 18.

16.

Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.

Demaris KM, White JR.

Drugs Today (Barc). 2013 May;49(5):289-301. doi: 10.1358/dot.2013.49.5.1964714.

PMID:
23724409
17.

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.

Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG.

Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165. Epub 2009 Dec 8.

18.

Dapagliflozin for the treatment of type 2 diabetes.

Anderson SL, Marrs JC.

Ann Pharmacother. 2012 Apr;46(4):590-8. doi: 10.1345/aph.1Q538. Epub 2012 Mar 20. Review.

PMID:
22433611
19.

Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.

Jabbour SA, Whaley JM, Tirmenstein M, Poucher SM, Reilly TP, Boulton DW, Saye J, List JF, Parikh S.

Postgrad Med. 2012 Jul;124(4):62-73. doi: 10.3810/pgm.2012.07.2569. Review.

PMID:
22913895
20.

Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans.

Suzuki M, Hiramatsu M, Fukazawa M, Matsumoto M, Honda K, Suzuki Y, Kawabe Y.

Diabetes Obes Metab. 2014 Jul;16(7):622-7. doi: 10.1111/dom.12259. Epub 2014 Jan 29.

PMID:
24400675
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk